Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.

The Journal of clinical endocrinology and metabolism - 1 Aug 2008

Canonico Marianne, Bouaziz Elodie, Carcaillon Laure, Verstuyft Céline, Guiochon-Mantel Anne, Becquemont Laurent, Scarabin Pierre-Yves

Abstract excerpt

CONTEXT: Hormone therapy increases the risk of venous thromboembolism (VTE) among postmenopausal women. This effect may be modulated by the expression of cytochromes P450 3A5 (CYP3A5) and 1A2 (CYP1A2) which are involved in the hepatic metabolism of estrogens. OBJECTIVE: The objective was to investigate the impact of CYP3A5 and CYP1A2 genetic polymorphisms on the association of VTE with hormone therapy. DESIGN: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Cytochrome P-450 CYP3A

Share to Estrogens

Share to Postmenopause

Share to Venous Thromboembolism

Source

Identifiers

PMID: 18628519
DOI: 10.1210/jc.2008-0450

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.PMID 18628519Read ↗

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.Semantic proximity Read ↗

Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study.Semantic proximity Read ↗

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read ↗

Risk factors for venous thromboembolism in pre-and postmenopausal women.Semantic proximity Read ↗

Genome-wide investigation of exogenous female hormones, genetic variation, and venous thromboembolism risk.Semantic proximity Read ↗

Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.Semantic proximity Read ↗

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.Semantic proximity Read ↗

Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.Semantic proximity Read ↗

Invited review: Pharmacogenetics of estrogen replacement therapy.Semantic proximity Read ↗

The genetic effects of hormones modulated by the Pituitary-Thyroid/Adrenal/Gonadal axis on the risk of developing venous thromboembolism: a mendelian randomization study.Semantic proximity Read ↗

Integrating Pharmacokinetic, Pharmacogenomic, and Clinical Risk Data to Individualise Hormonal Contraception and Minimise Thrombotic Risk: A Translational Framework.Semantic proximity Read ↗

Oral contraceptives, hormone therapy and cardiovascular risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.